Amex grants extensions for Hemispherx to file 10-K, 10-Q

By Lisa Kerner

Erie, Pa., May 12 - Hemispherx Biopharma, Inc. has been granted extensions by the American Stock Exchange to file its form 10-K for the year ended Dec. 31, 2005 and its form 10-Q for the period ended March 31.

Amex had notified the company that it was not in compliance with Sections 134 and 1101 of the Amex Company Guide.

After reviewing Hemispherx' plan to regain compliance, Amex granted filing extensions of June 2 for the 10-K and June 30 for the 10-Q, according to a news release.

Hemispherx said the delay in the 10-K filing was due to application of accounting principles related to complex convertible debentures on the books. It does not affect the company's revenues, cash flows from operations or liquidity.

"The company and our auditors are diligently focused on resolving this issue in a timely manner," chairman and chief executive officer Dr. William Carter said in the release.

Hemispherx is a Philadelphia-based biopharmaceutical company that develops drugs for the treatment of viral and immune-based chronic disorders.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.